Tecan Revises 2024 Outlook Amid Market Challenges
Tecan reports lower H1 2024 sales, revises full-year outlook due to biopharma sector weakness and market challenges in China.
- Latest
- Trending
Tecan reports lower H1 2024 sales, revises full-year outlook due to biopharma sector weakness and market challenges in China.
Crane NXT lifts full-year sales forecast, reports 5% Q2 growth, and plans strategic acquisitions to reach $3 billion revenue goal.
Hapag-Lloyd reports robust H1 2024, with $0.9B EBITDA, despite disruptions. Prepares for Gemini network launch amid market uncertainties.
Columbus officials confirm sensitive data leaked in cyber attack, affecting justice system databases.
DMarket and Ethereum drive NFT market growth with impressive sales, highlighting a surge in digital asset demand.
Speculators reach record short bets on 5-year Treasuries, as 10-year shorts rise to highest since January, reveals CFTC data.
Dogecoin's active users soar 32%. Can the price follow the trend? Explore the implications for DOGE's market potential.
Digihost Technology's Q2 2024 revenue rose 57%, beating analyst estimates by 14%, despite a widened net loss.
BlackRock's ETFs dominate Bitcoin and Ethereum with significant inflows, despite some outflows from other issuers.
Tencent Music shares fall 6% as Q2 earnings miss, despite a 29.4% rise in music subscription revenue.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.